ARHGAP33 and polycystic ovary syndrome: Additionally, Arhgap33 displayed high diagnostic prediction of metabolic syndrome in patients with polycystic ovarian syndrome, which may be due to disrupted regulation of glucose transport, supporting its role in metabolic disruption [83].